Struggling bluebird bio to go private for less than $30m
Bluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time …
-
-
Pfizer shelves haemophilia gene therapy Beqvez amid low demand
Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low demand and interest. A Pfizer …
-
UroGen acquires IconOVir’s oncolytic virus assets
UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to the oncolytic virus ICVB-1042. The company issued …
-
GLP-1 receptor agonists could hold promise for opioid use disorder treatment
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby …
-
How CNS researchers are handling clinical trial turbulence
The field of central nervous system (CNS) drug development is awash with activity. Data from GlobalData’s drugs database, as of …
-
NICE green lights two blood cancer therapies for NHS use
Two blood cancer treatments will now be available on the UK’s National Health Service (NHS) following recommendations from the National …
-
Incyte and Genesis collaborate on small-molecule medicines
Incyte and Genesis Therapeutics have entered a strategic partnership aimed at the research, discovery and development of new small-molecule medicines. Incyte …
-
Navigating the Complexities of Sustainable Specialty Pharma Supply Chains
The pharmaceutical world is changing. Sales of personalised therapies, for example, will skyrocket from $8 billion in 2022 to a …
-
Japan’s MHLW approves CSL Behring’s Andembry to stop HAE attacks
CSL Behring KK has gained approval from Japan's Ministry of Health, Labour and Welfare (MHLW) to manufacture and market subcutaneous …
-
FibroGen sells China unit to AstraZeneca for $160m
AstraZeneca has agreed to acquire FibroGen’s China subsidiary for approximately $160m, securing full control over the anaemia drug roxadustat in …
-
Zealand Pharma steadfastly upholds amylin-based obesity drug strategy
Zealand Pharma’s search for a partner for its amylin-based obesity therapy petrelintide remains ongoing, with no agreement announced in its …
-
X4 and taiba to distribute WHIM syndrome therapy in Middle East
US-based X4 Pharmaceuticals has entered an exclusive agreement with United Arab Emirates (UAE)-based pharmaceutical products wholesaler taiba rare to distribute …
-
Key pharma launch trends in 2024
Drug manufacturers faced a variety of hurdles in 2024. Healthcare system reforms, preparation for the EU joint clinical assessments (JCAs) …
-
WHO targets over half a million children in Gaza for polio vaccine drive
The World Health Organization (WHO) said it will conduct another mass vaccination round in the Gaza Strip to protect children …
-
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancer
ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an alternative source …
